Hyperforin is a phytochemical produced by some of the members of the plant genus Hypericum, notably Hypericum perforatum (St John's wort).[2] Hyperforin may be involved in the pharmacological effects of St. John's wort.[2] More specifically for the antidepressant effects of St. John's wort.[3][4][5][6][7][8]

Clinical data
Routes of
ATC code
  • none
Legal status
Legal status
  • US: OTC
  • unscheduled in most countries, with the notable exception of Ireland (Rx-only)[1]
Pharmacokinetic data
MetabolismHepatic and CYP3A & CYP2B
Elimination half-life9-19.64 hours
CAS Number
PubChem CID
ECHA InfoCard100.112.565
Chemical and physical data
Molar mass536.797 g·mol−1
3D model (JSmol)
Melting point79–80 °C (174–176 °F)
Solubility in water0.66 mg/mL (20 °C)
 NY (what is this?)  (verify)


Hyperforin has only been found in significant amounts in Hypericum perforatum with other related species such as Hypericum calycinum containing lower levels of the phytochemical.[2] It accumulates in oil glands, pistils, and fruits, probably as a plant defensive compound.[9] The first natural extractions were done with ethanol and afforded a 7:1 yield of crude extract to phytochemical however, this technique produced a mixture of hyperforin and adhyperforin. [10][11][12] The extraction technique has since been modernized using lipophilic liquid CO2 extraction to afford a 3:1 crude to phytochemical extraction which is then further purified away from adhyperforin. [13][14][15] This CO2 extraction is rather tricky still because typical 'supercritical' conditions extract less material whereas anything over 40°C will degrade Hyperforin.[16][17][18] Other Hypericum species contain low amounts of hyperforin.[19]


Hyperforin is a prenylated phloroglucinol derivative and is a member of the Polycyclic polyprenylated acylphloroglucinol family, also known as the PPAP family. Hyperforin is a unique PPAP because it consists of a C8 quaternary stereocenter which was a synthetic challenge unlike other PPAP synthetic targets.[20][21][22] The structure of hyperforin was elucidated by a research group from the Shemyakin Institute of Bio-organic Chemistry (USSR Academy of Sciences in Moscow) and published in 1975.[23][24] A total synthesis of the non-natural hyperforin enantiomer was reported in 2010 which required approximately 50 synthetic transformations and relied heavily on basic organic reactivity.[25] In 2010, an enantioselective total synthesis of the correct enantiomer was disclosed. The retrosynthetic analysis was inspired by hyperforin's structural symmetry and biosynthetic pathway. The synthetic route undertaken generated a prostereogenic intermediate which then established the synthetically challenging C8 stereocenter and facilitated the stereochemical outcomes for the remainder of the synthesis .[26]

Hyperforin is unstable in the presence of light and oxygen.[27] Frequent oxidized forms contain a C3 to C9 hemiketal/heterocyclic bridge or will form furan/pyran derivatives.[28][29]


Some pharmacokinetic data on hyperforin is available for an extract containing 5% hyperforin. Maximal plasma levels (Cmax) in human volunteers were reached 3.5 hours after administration of an extract containing 14.8 mg hyperforin. Biological half-life (t1/2) and mean residence time were 9 hours and 12 hours, respectively, with an estimated steady state plasma concentration of 100 ng/mL (approx. 180 nM) for 3 doses per day. Linear plasma concentrations were observed within a normal dosage range and no accumulation occurred.[30]

In healthy male volunteers, 612 mg dry extract of St. John's wort produced hyperforin pharmacokinetics characterised by a half life of 19.64 hours.[31]


Hyperforin may be a constituent responsible for the antidepressant and anxiolytic properties of the extracts of St. John's wort.[2][32] In vitro, it acted as a reuptake inhibitor of monoamines (MRI), including serotonin, norepinephrine, dopamine, and of GABA and glutamate, with IC50 values of 0.05-0.10 μg/mL for all compounds, with the exception of glutamate, which is in the 0.5 μg/mL range.[33] In other laboratory studies, hyperforin induced cytochrome P450 enzymes CYP3A4 and CYP2C9 by binding to and activating the pregnane X receptor.[34]

Reuptake Inhibition
Neurotransmitter IC50 (nanomoles)[33]
Norepinephrine80 ± 24
Dopamine102 ± 19
GABA184 ± 41
5-HT205 ± 45
Glutamate829 ± 687
Binding affinity (human receptors)
Receptor Ki (nanomoles)
Natural and semi-synthetic analogues of Hyperforin
Hyperforin trimethoxybenzoate
Hyperforin nicotinate
Adhyperforin Aristoforin Hyperforin trimethoxybenzoate Tetrahydrohyperforin Octahydrohyperforin Hyperforin nicotinate

Antidepressant research

Two meta-analyses of preliminary clinical trials evaluating the efficacy of St. John's wort for treating mild-to-moderate depression indicated a response similar to selective serotonin reuptake inhibitors and with better tolerance, although the long-term generalization of study results was limited by the short duration (4-12 weeks) of reviewed studies.[36][37]

See also


  1. http://www.irishhealth.com/article.html?id=24993
  2. "Hyperforin". PubChem, US National Library of Medicine. 8 September 2018. Retrieved 13 September 2018.
  3. Behav. Brain Res. 2019, 372
  4. Eur. J. Pharm. Biopharm. 2018, 126, 10–26.
  5. Chem. Rev. 2006, 106 (9), 3963–3986.
  6. Life Sci. 2004, 75 (23), 2841–2850.
  7. Sci. Rep. 2014, 4, 1–12.
  8. Biochem. Pharmacol. 2017, 129, 96–107.
  9. Beerhues L (2006). "Hyperforin". Phytochemistry. 67 (20): 2201–7. doi:10.1016/j.phytochem.2006.08.017. PMID 16973193.
  10. Eur. J. Pharm. Biopharm. 2018, 126, 10–26
  11. Fitoterapia 2003, 74 (5), 439–444.
  12. J. Nat. Prod. 1999, 62 (5), 770–772.
  13. Eur. J. Pharm. Biopharm. 2018, 126, 10–26
  14. Fitoterapia 2003, 74 (5), 439–444.
  15. J. Nat. Prod. 1999, 62 (5), 770–772.
  16. Eur. J. Pharm. Biopharm. 2018, 126, 10–26
  17. Fitoterapia 2003, 74 (5), 439–444.
  18. J. Nat. Prod. 1999, 62 (5), 770–772.
  19. Smelcerovic A, Spiteller M (March 2006). "Phytochemical analysis of nine Hypericum L. species from Serbia and the F.Y.R. Macedonia". Die Pharmazie. 61 (3): 251–2. PMID 16599273.
  20. Eur. J. Pharm. Biopharm. 2018, 126, 10–26
  21. Chem. Rev. 2006, 106 (9), 3963–3986
  22. J. Am. Chem. Soc. 2013; 135: 644-647
  23. Bystrov NS; Gupta ShR; Dobrynin VN; Kolosov MN; Chernov BK (January 1976). "[Structure of the antibiotic hyperforin]". Doklady Akademii Nauk SSSR (in Russian). 226 (1): 88–90. PMID 1248360.
  24. Bystrov NS, Chernov BK, Dobrynin VN, Kolosov MN (1975). "[The structure of hyperforin]". Tetrahedron Letters. 16 (32): 2791–2794. doi:10.1016/S0040-4039(00)75241-5.
  25. Shimizu Y, Shi SL, Usuda H, Kanai M, Shibasaki M (February 2010). "Catalytic Asymmetric Total Synthesis of ent-Hyperforin". Angew Chem Int Ed. 49 (6): 1103–6. doi:10.1002/anie.200906678. PMID 20063336.
  26. Sparling B, Moebius D, Shair M (December 2012). "Enantioselective Total Synthesis of Hyperforin". J Am Chem Soc (Submitted manuscript). 135 (2): 644–7. doi:10.1021/ja312150d. PMID 23270309.
  27. Liu, F; Pan, C; Drumm, P; Ang, CY (February 2005). "Liquid chromatography-mass spectrometry studies of St. John's wort methanol extraction: active constituents and their transformation". Journal of Pharmaceutical and Biomedical Analysis. 37 (2): 303–12. doi:10.1016/j.jpba.2004.10.034. PMID 15708671.
  28. Fitoterapia 2003, 74 (5), 439–444.
  29. J. Nat. Prod. 1999, 62 (5), 770–772
  30. Biber, A; Fischer, H; Römer, A; Chatterjee, SS (June 1998). "Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers". Pharmacopsychiatry. 31 (Suppl 1): 36–43. doi:10.1055/s-2007-979344. PMID 9684946.
  31. Schulz, HU; Schürer, M; Bässler, D; Weiser, D (2005). "Investigation of the Bioavailability of Hypericin, Pseudohypericin, Hyperforin and the Flavonoids Quercetin and Isorhamnetin Following Single and Multiple Oral Dosing of a Hypericum Extract Containing Tablet". Arzneimittelforschung. 55 (1): 15–22. doi:10.1055/s-0031-1296820. PMID 15727160.
  32. Newall, Carol A.; Joanne Barnes; Anderson, Linda R. (2002). Herbal medicines: a guide for healthcare professionals. London: Pharmaceutical Press. ISBN 978-0-85369-474-8.
  33. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Müller WE (1998). "Hyperforin as a possible antidepressant component of hypericum extracts". Life Sci. 63 (6): 499–510. doi:10.1016/S0024-3205(98)00299-9. PMID 9718074.
  34. Moore LB, Goodwin B, Jones SA, et al. (June 2000). "St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor". Proceedings of the National Academy of Sciences of the United States of America. 97 (13): 7500–2. doi:10.1073/pnas.130155097. PMC 16574. PMID 10852961.
  35. "Hyperforin". BindingDB. Retrieved 5 March 2015.
  36. Ng QX, Venkatanarayanan N, Ho CY (March 2017). "Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis". Journal of Affective Disorders. 210: 211–221. doi:10.1016/j.jad.2016.12.048. PMID 28064110. 27 clinical trials with a total of 3808 patients were reviewed [...] For patients with mild-to-moderate depression, St John's wort has comparable efficacy and safety when compared to SSRIs. Follow-up studies carried out over a longer duration should be planned to ascertain its benefits.
  37. Cui YH, Zheng Y (2016). "A meta-analysis on the efficacy and safety of St John's wort extract in depression therapy in comparison with selective serotonin reuptake inhibitors in adults". Neuropsychiatric Disease and Treatment. 12: 1715–23. doi:10.2147/NDT.S106752. PMC 4946846. PMID 27468236. A total of 3,126 patients with depression were included. St John’s wort extract did not differ from SSRIs in clinical response, remission, and mean reduction in Hamilton Rating Scale for Depression score. [...] Both St John’s wort extract and SSRIs are effective in treating mild-to-moderate depression. St John’s wort extract is safer than SSRIs.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.